Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
Yasuo TerauchiMasahiro TamuraMasayuki SendaRyoji GunjiKohei KakuPublished in: Diabetes, obesity & metabolism (2018)
This study demonstrates the safety and efficacy of tofogliflozin as add-on to insulin therapy in type 2 diabetes mellitus patients, offering a new therapeutic solution to diabetes management.
Keyphrases
- randomized controlled trial
- study protocol
- open label
- placebo controlled
- double blind
- type diabetes
- phase iii
- clinical trial
- phase ii
- glycemic control
- end stage renal disease
- phase ii study
- newly diagnosed
- ejection fraction
- chronic kidney disease
- cardiovascular disease
- peritoneal dialysis
- patient reported outcomes
- prognostic factors
- rectal cancer
- bone marrow
- patient reported
- cell therapy